• Intelligent Bio Solutions completed a clinical interference study supporting its FDA 510(k) filing for U.S. clearance to detect codeine.
• Results have not been presented; data analysis is underway with independent verification planned using LC-MS/MS.
• Study indicates common external contaminants on fingertips did not compromise system performance in field-like conditions.
• Work feeds a broader evidence package; the 510(k) submission remains targeted for calendar H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030830PRIMZONEFULLFEED9802308) on August 03, 2026, and is solely responsible for the information contained therein.